Navigation Links
Cancer drug boosts levels of vascular-protective gene, KLF2
Date:6/11/2014

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

In 2008, the Food and Drug Administration approved bortezomib (Velcade) to treat multiple myeloma, which is a type of bone cancer and mantle cell lymphoma a particularly aggressive form of non-Hodgkin lymphoma. In addition to attacking cancer cells, the drug has been shown to help prevent clot development common to many forms of the disease.

As hematologist Lalitha Nayak, MD, an assistant professor of medicine, reports in the June 12 edition of the journal Blood, the anti-thrombotic effects of bortezomib are determined by KLF2, part of a family of Kruppel-like factors master regulators of vascular health.

"We thought that if we could figure out how bortezomib protects against thrombosis," Nayak explained, "we might be closer to understanding why our patients develop blood clots and what could be done to help them."

She is also a member of the Mukesh Jain, MD, Laboratory at Case Western Reserve University, so she was also well aware of the laboratory's work in Kruppel-like factors. KLF2 specifically is a protein in the Kruppel-like gene family of transcription factors that prevents clot formation in the body's major blood vessels. (Transcription factor is a protein that controls the flow of genetic information that provides instructions to our bodies on how to function.)

"Work from our laboratory during the past decade has established Kruppel-like factors as nodal regulators of vascular health," said Jain, cardiologist and professor of medicine. "It was a good educated guess by Dr. Nayak that bortezomib's positive effect on vascular function was linked to a member of this family."

Nayak concurs. "We hypothesized that bortezomib protects against thrombosis by increasing KLF levels," she said.

She took her curious, yet pleasantly surprising, observation regarding bortezomib's thromboprotective effect to the laboratory. In her investigations, Nayak first showed that bortezomib treatment rendered normal mice resistant to clot formation. Next, she demonstrated that among the 17 members of the KLF family, bortezomib specifically and potently induced KLF2 levels. Finally, she confirmed the importance of KLF2 by injecting bortezomib into mice missing the KLF2 gene. Although bortezomib treatment protected normal mice from thrombosis, this effect was absent in the KLF2-deficient mice. "This taught us how important KLF2 is for the ability of bortezomib to protect against thrombosis," Nayak said.

The results of this study have the potential to alter the management of thrombosis in patients who have a predisposition to clot formation and especially in situations where present modalities of therapy are inadequate. One example of such a condition is antiphospholipid antibody syndrome (APLS), a condition where patients have an increased risk for blood clots in both arteries and veins. The disease often affects young women, and there is no effective antithrombotic strategy for this group of patients. Moreover, currently used antithrombotic therapies are associated with an increased risk for bleeding. Although bortezomib protects against thrombosis, it comes with no concurrent increase in bleeding, making this drug a potential treatment alternative for APLS patients.

"Vascular clots are the No. 1 cause of death and disability worldwide," Nayak said. "Our studies show that increasing KLF2 levels provides a favorable thromboprotective effect."

At present, KLF2 levels can be pharmacologically altered with bortezomib. Importantly, the study showed that bortezomib can induce KLF2 levels and provide protection against thrombosis, even when used at much lower doses than those used to treat patients with myeloma.

"We are not trying to kill a cancer, so we started with smaller doses of the medication," Nayak said. "In our study, we were able to use one-third of the usual anti-tumor dose used in animal studies and found that this lower dose still resulted in a good antithrombotic effect."

Additionally, KLF2 itself could also serve as a biomarker, Jain said. "Examining KLF2 levels in blood cells might inform clinicians about a patient's risk for thrombotic events," Jain said. "This would help us identify patients who may benefit from upfront preventive therapy for thrombosis."


'/>"/>

Contact: Jeannette Spalding
jeannette.spalding@case.edu
216-368-3004
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a ... throughout the Five Boroughs, is launching a charity drive to raise funds that will ... traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the MCL, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John ... by donating a portion of proceeds to two local organizations: North Chicago Animal Control ... & Friends is a team of authorized and trained volunteers who support rescued ...
(Date:12/7/2016)... ... ... The medical profession is well aware that heart attacks do indeed increase ... attacks among 138,602 people recorded a 35% higher number of heart attacks in December ... course–no time of year is a good time for a heart attack! In the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 ... of three acupuncturists to help patients realize their family building goals. Acupuncture ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers to ... , “Fred Rides a Train” is the creation of published author, Janet Morrison, ... teen years in Michigan. The "Fred, the Dog" series is her first attempt at ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Kan. , Dec. 7, 2016   Rx Savings ... West Virginia and its Public Employees Insurance Agency ... members access to their innovative healthcare software, ultimately saving money ... with PEIA and provide its members with access to our ... or a more effective, affordable therapy can be found," says ...
(Date:12/7/2016)... Dec. 7, 2016  Varian Medical Systems (NYSE: ... previously announced plans to separate its Imaging Components business.  ... tax-free distribution to Varian stockholders of common stock in ... will hold the Imaging Components business.  As part of ... by the end of January 2017, Varian will receive ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology: